According to IMARC Group, the global Surgical Site Infection Control Market size reached USD 4.9 Billion in 2025 and is projected to reach USD 6.8 Billion by 2034, expanding at a CAGR of 3.45% during 2026–2034. This steady growth reflects the increasing number of surgical procedures worldwide, growing awareness about healthcare-associated infections (HAIs), heightened focus on patient safety, and surging global healthcare expenditure.

Surgical Site Infection Control Market: Industry Overview

Surgical site infections are infections that occur after surgery in the part of the body where the surgery took place. They can involve the skin, underlying tissue, organs, or implanted material. SSIs represent one of the most common healthcare-associated infections globally, placing an enormous burden on healthcare systems and patients alike.

The surgical site infection control market encompasses a comprehensive range of products and solutions, including:

•          Antibiotic Prophylaxis Products: Administered pre-operatively to minimize bacterial contamination at the surgical site

•          Wound Care Dressings: Advanced dressings designed to promote healing and prevent infection post-surgery

•          Surgical Drapes: Sterile barriers that isolate the surgical field from surrounding non-sterile areas

•          Surgical Clippers: Used for safe, pre-operative hair removal at surgical sites

•          Antiseptics and Disinfectants: Chemical agents for skin preparation and surface decontamination

•          Wound Irrigation Products: Solutions for cleansing surgical wounds and reducing bacterial load

Global Market Overview & Surgical Site Infection Control Market Size Statistics

Below are the key Surgical Site Infection Control Market Size statistics drawn from IMARC Group's comprehensive market analysis:

Request for a Sample Report for Detailed Market Insights Evaluation: https://www.imarcgroup.com/surgical-site-infection-control-market/requestsample

Key Surgical Site Infection Control Market Growth Drivers & Trends in 2026

Several powerful forces are shaping the Surgical Site Infection Control Market Growth and fueling steady expansion across global healthcare markets:

1. Rising Geriatric Population and Surgical Volumes

Global demographic shifts are resulting in a rapidly aging population. Older adults are more susceptible to SSIs due to weakened immune systems, reduced tissue healing capacity, and the presence of comorbidities such as diabetes and cardiovascular disease. As the geriatric population grows, so does the number of surgical procedures performed on older adults — driving heightened demand for effective infection control measures.

2. Increasing Healthcare Infrastructure Development

Healthcare infrastructure expansion, particularly in emerging markets, is catalyzing the Surgical Site Infection Control Market Share growth. Governments and private investors are channeling resources into modern surgical facilities, driving the adoption of advanced infection control protocols and products. Emerging economies in Asia Pacific, Latin America, and the Middle East are experiencing particularly rapid healthcare infrastructure buildout.

3. Technological Advancements in Infection Control Products

Continuous innovation in infection control is a major driver of Surgical Site Infection Control Market Trends. Advances include antimicrobial coatings for surgical instruments, next-generation wound dressings incorporating bioelectric technology, novel surgical materials with anti-infective properties, and robotic-assisted surgery techniques that minimize tissue trauma and infection risk. These innovations are continuously raising the bar for SSI prevention efficacy.

4. Stringent Regulatory Standards and Clinical Guidelines

Governing and non-governing agencies worldwide are introducing and enforcing stringent SSI prevention guidelines and training programs. Regulatory frameworks mandating infection control compliance in surgical settings are compelling healthcare facilities to invest in approved products and protocols, thereby boosting market demand.

5. Advances in Research Studies and Clinical Trials

Active research and clinical trial pipelines are accelerating the development of innovative SSI control products. Clinical evidence from large-scale trials — such as the SHIELD II Phase 3 study on D-PLEX100 for SSI prevention in abdominal colorectal procedures — is guiding best practices, improving compliance, and reducing overall SSI incidence, strengthening confidence in advanced infection control solutions.

6. Growing Focus on Patient Safety and Healthcare Quality

Healthcare providers and institutions are increasingly focused on patient outcomes and maintaining strong reputations. Preventing SSIs is central to quality improvement efforts, as SSIs can cause significant morbidity, prolong hospital stays, increase costs, and in severe cases, result in mortality. This focus is driving adoption of comprehensive infection control programs across hospitals and ambulatory surgical centers.

Key Surgical Site Infection Control Market Segmentation

By Product

Antibiotic Prophylaxis Products – Largest Segment

Antibiotic prophylaxis products dominate the product segment of the Surgical Site Infection Control Market Share, as they form the cornerstone of SSI prevention strategies. Administered within 60 minutes before surgical incision, these products are tailored to the specific requirements of different surgical procedures — for example, coverage against Staphylococcus aureus for orthopedic surgeries, and gram-negative and anaerobic bacteria coverage for colorectal surgeries.

Other product segments include:

•          Wound Care Dressings

•          Surgical Drapes

•          Surgical Clippers

•          Antiseptics and Disinfectants

•          Wound Irrigation Products

By Infection Type

Superficial Incisional SSI – Largest Segment

Superficial incisional SSIs represent the largest infection type segment, accounting for the majority of total SSI cases globally — with research indicating they constitute approximately 59% of all SSI patients. These infections occur within 30 days post-surgery and involve the skin and subcutaneous tissue. Their relatively high incidence makes them the primary focus of infection control protocols.

•          Deep Incisional SSI

•          Organ or Space SSI

By Surgery Type

Cesarean Section – Largest Segment

Cesarean sections hold the largest surgery type market share, driven by their high and increasing global prevalence. According to WHO, C-sections accounted for more than 21% of all childbirths in 2021, with projections indicating this figure may rise to nearly 29% by 2030. The proximity of the surgical site to the genital and gastrointestinal tracts — combined with the high volume of procedures — makes SSI prevention in C-sections a top clinical priority.

•          Gastric Bypass

•          Cataract Surgery

•          Dental Restoration

By End User

Hospitals – Largest Segment

Hospitals account for the dominant end-user share of the Surgical Site Infection Control Market, driven by their high patient volumes, complex multi-departmental surgical requirements, and stringent regulatory obligations. Patient safety imperatives, quality improvement mandates, and financial considerations related to SSI-induced complications all compel hospitals to invest heavily in comprehensive infection control programs.

•          Ambulatory Surgical Centers

•          Others

Regional Market Analysis

Connect for Detailed Segmentation Analysis – Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=5669&flag=C

Leading Players in the Surgical Site Infection Control Industry

The global surgical site infection control market features established medical technology leaders and specialized infection prevention companies. Key companies covered in the IMARC Group report include:

•          3M Company

•          Ansell Limited

•          Becton Dickinson and Company

•          bioMerieux SA. (Institut Mérieux)

•          Covalon Technologies Ltd.

•          GAMA Healthcare Ltd.

•          Getinge AB (Carl Bennet AB)

•          Johnson & Johnson

•          Kimberly-Clark Corporation

•          Mölnlycke Health Care AB

•          Prescient Surgical

•          Steris Corporation

Latest Industry Developments

May 2024 – Nanordica Medical

Nanordica Medical, an Estonian medical technology firm, secured €1.75 million in funding to bring first-in-class wound care solutions to market, targeting the treatment of serious wounds with advanced infection prevention capabilities.

April 2024 – Vomaris

Vomaris launched PowerHeal, a bioelectric bandage that received FDA approval for over-the-counter use in the management of wounds. The innovative bioelectric technology represents a significant advance in wound care and SSI prevention.

February 2024 – PolyPid Ltd.

PolyPid Ltd., a biopharmaceutical company dedicated to improving surgical outcomes, announced considerable progress in its SHIELD II Phase 3 clinical study, after enrolling its 100th patient. The research assessed the efficacy of D-PLEX100, a product candidate intended to prevent SSIs in abdominal colorectal procedures — with top-line results anticipated in the second half of 2024.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Technology, Construction, Healthcare, Energy, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104